Ask AI
Test Your Skills: 1L HR Pos HER2 Pos mBC
Management of a Patient With Newly Diagnosed HR+/HER2+ mBC on Medication for Comorbidities

Released: April 21, 2024

Expiration: October 20, 2024

Activity

Progress
1
Course Completed

  1. Cobleigh M, Yardley DA, Brufsky AM, et al. Baseline characteristics, treatment patterns, and outcomes in patients with HER2-positive metastatic breast cancer by hormone receptor status from SystHERs. Clin Cancer Res. 2020;26:1105-1113.
  2. Giordano SH, Franzoi MAB, Temin S, et al. Systemic therapy for advanced human epidermal growth factor receptor 2-positive breast cancer: ASCO guideline update. J Clin Oncol. 2022;40:2612-2635.
  3. Rimawi M, Ferrero JM, de la Haba-Rodriguez J, et al. First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol. 2018;36:2826-2835.
  4. Metzger O, Mandrekar S, DeMichele A, et al. AFT-38 PATINA: a randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy vs. anti-HER2 therapy + endocrine therapy after induction treatment for hormone receptor-positive (HR+)/HER2-positive metastatic breast cancer. Presented at: 2024 San Antonio Breast Cancer Symposium; December 10-13, 2024. Abstract GS2-12.
  5. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: breast cancer. v3.2025. nccn.org. Accessed April 7, 2025.
  6. Baselga J, Cortés J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012;366:109-119.
  7. Graff SL, Yan F, Abdou Y. Newly approved and emerging agents in HER2-positive metastatic breast cancer. Clin Breast Cancer. 2023;23:e380-e393.
  8. Trastuzumab deruxtecan [prescribing information]. Basking Ridge, NJ; Daiichi Sankyo. 2024
  9. Ramakrishna N, Anders CK, Lin NU, et al. Management of advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: ASCO guideline update. J Clin Oncol. 2022;40:2636-2655.
  10. Wolff AC, Hammond MEH, Allison KH, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused update. J Clin Oncol. 2018;36:2105-2122.
  11. Wolff AC, Somerfield MR, Dowsett M, et al. Human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med. 2023;147:993-1000.